Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: Synthesis and determination of affinities at D2, 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors

European Journal of Medicinal Chemistry

Volumn 35, Issue 1, 2000, Pages 83-95

  Masaguer, Christian F ^a   Raviña, Enrique ^a   Fontenla, José Angel ^b   Brea, José ^b   Tristán, Helena ^b   Loza, María Isabel ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Univ Santiago C   (Spain)

Author keywords

Antipsychotics; Dopamine D2 receptors; Serotonin 5 HT2 receptors

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUANISONE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE;

ARTICLE; CATALYSIS; CYCLIZATION; DRUG ACTIVITY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; RECEPTOR AFFINITY;

EID: 0034012571     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(00)00109-4     Document Type: Article

References (66)

1. Howard H.R., Seeger T.F. Bristol J.A. Annual Reports in Medicinal Chemistry vol. 28. 1993;39 Academic Press.
2. Schaus J.M., Bymaster F.P. Bristol J.A. Annual Reports in Medicinal Chemistry vol. 33. 1998;1 Academic Press.
3. Kennedy J.L., Billett E.A., Macciardi F.M., Verga M., Parsons T.J., Meltzer H.Y., Lieberman J., Buchanan J.A. Am. J. Med. Genet. 60:1995;558-562.
4. Kulagowski J.J., Broughton H.B., Curtis N.R., Mawer I.M., Ridgill M.P., Baker R., et al. J. Med. Chem. 39:1996;1941-1942.
5. Sanner M.A., Chappie T.A., Dunaiskis A.R., Fliri A.F., Desai K.A., Zorn S.H., et al. Bioorg. Med. Chem. Lett. 8:1998;725-730.
6. Bristow L.J., Kramer M.S., Kulagowski J., Patel S., Ragan C.I., Seabrook G.R. Trends Pharmacol. Sci. 18:1997;186-187.
7. Megens A.H.P., Kennis L.E.J. Ellis G.P, Luscombe D.K. Progress in Medicinal Chemistry vol. 33. 1996;186 Elsevier Science.
8. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Neuropsychopharmacol. 14:1996;111-123.
9. Conley R.R., Buchanan R.W. Schizophrenia Bull. 23:1997;663-674.
10. Sanders-Bush E., Mayer S.E. Hardman J.G, Limbird L.E, Molinoff P.B, Ruddon R.W, Goodman A. The Pharmacological Basis of Therapeutics, 9th. 1996;249-263 McGraw-Hill.
11. Roth B.L., Meltzer H.Y. Bloom F.E, Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1215-1227 Raven Press Ltd., New York.
12. Meltzer H.Y., Atypical Antipsychotic Drugs: Which Receptors are Relevant? IBS's International Conference on Serotonin receptors. Central Nervous System. Targets for new therapeutic agents, Philadelphia, 1996.
13. Hoyer D., Martin G.R. Behav. Brain Res. 73:1996;263-268.
14. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. Pharmacol. Rev. 46:1994;157-203.
15. Erdmann J., Nothen M.M., Shimron-Abarbanell D., Rietschel M., Albus M., Borrmann M., et al. Mol. Psychiatry. 1:1996;392-397.
16. Baxter G.S., Kennett G., Blaney F., Blackney T. Trends Pharmacol. Sci. 16:1995;105-109.
17. Meltzer H.C., Matsubara S., Lee J.C. Psychopharmacol. Bull. 253:1989;390-392.
18. Roth B.L., Tandra S., Burgess L.H., Sibley D.R., Meltzer H.Y. Psychopharmacology. 120:1995;365-368.
19. Sipes T.E., Geyer M.A. Brain Res. 761:1997;97-104.
20. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Kumagai T., et al. Br. J. Pharmacol. 121:1997;515-525.
21. Green M.F., Marshall J.R.B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., Mintz J. Am. J. Psychiatry. 154:1997;799-804.
22. Martin P., Waters N., Carlsson A., Carlsson M.L. J. Neural Transm. 104:1997;561-564.
23. Meltzer H.Y. Eur. Neuropsychophamacol. 6:1996;S322.
24. Roth B.L., Meltzer H.Y., Khan N. Adv. Pharmacol. 42:1998;482-485.
25. Reavill C., Kettle A., Holland V., Riley G., Blackburn T.P. Br. J. Pharmacol. 126:1999;572-574.
26. Wainscott D.B., Lucaites V.L., Kursar J.D., Baez M., Nelson D.L. J. Pharmacol. Exp. Ther. 276:1996;720-727.
27. Baxter G.S., Kennett G., Blaney F., Blackney T. Trends Pharmacol. Sci. 16:1995;105-109.
28. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. Pharmacol. Rev. 46:1994;157-203.
29. Schmuck K., Ullmer C., Engels P., Lubbert H. FEBS Lett. 342:1994;85-90.
30. Kursar J.D., Nelson D.L., Wainscott D.B., Baez M. Mol. Pharmacol. 46:1994;227-234.
31. Kursar J.D., Nelson D.L., Wainscott D.B., Cohen M.L., Baez M. Mol. Pharmacol. 42:1992;549-557.
32. Foguet M., Hoyer D., Pardo L.A., Parekh A., Kluxen F.W., Kalkman H.O., Stuhmer W., Lubbert H. EMBO J. 11:1992;3481-3487.
33. Duxon M.S., Flanigan T.P., Reavley A.C., Baxter G.S., Blackburn T.P., Fone K.C.F. Neuroscience. 76:1997;323-329.
34. Lieberman J.A., Hohn C.A., Mikane J., Rai K., Pisciotta A.V., Salz B.L., Howard A. J. Clin. Psychiatry. 49:1988;271-277.
35. Cortizo L., Santana L., Raviña E., Orallo F., Fontenla J.A., Castro E., de Ceballos M. J. Med. Chem. 34:1991;2242-2247.
36. Fontenla J.A., Osuna J.A., Rosa E., Castro E., Loza I., G-Ferreiro T., et al. J. Med. Chem. 37:1994;2564-2573.
37. Raviña E., Fueyo J., Masaguer C.F., Negreira J., Cid J., Loza I., et al. Chem. Pharm. Bull. 44:1996;534-541.
38. Masaguer C.F., Casariego I., Raviña E. Chem. Pharm. Bull. 47:1999;621-632.
39. Raviña E., Negreira J., Cid J., Masaguer C.F., Rosa E., Rivas M.E., et al. J. Med. Chem. 42:1999;2774-2797.
40. Compound QF 0510B does not produce catalepsy at doses as high as 20 mg/kg.
41. Masaguer C.F., Formoso E., Raviña E., Tristán H., Loza M.I., Rivas E., Fontenla J.A. Bioorg. Med. Chem. Lett. 8:1998;3571-3576.
42. Herndon J.L., Ismaiel A., Ingher S.P., Teitler M., Glennon R.A. J. Med. Chem. 35:1992;4903-4910.
43. Ismaiel A.M., Arruda K., Teitler M., Glennon R.A. J. Med. Chem. 38:1995;1196-1202.
44. Shustke G.M., Setescak L.L., Allen R.C., Davis L., Effland R.E., Ranbom K., et al. J. Med. Chem. 25:1982;36-44.
45. Strupezewski J.T., Allen R.C., Gardenr B.A., Schimid B.L., Stache U., Glankowzki E.J., et al. J. Med. Chem. 28:1985;761-769.
46. Kuehne M.E., Lambert B.F. J. Am. Chem. Soc. 81:1959;4278-4287.
47. Chapman O.L., Fitton P. J. Am. Chem. Soc. 85:1963;41-47.
48. Casariego I., Masaguer C.F., Raviña E. Tetrahedron Lett. 31:1997;5555-5558.
49. Hughes D.L., Zhao D.J. Org. Chem. 58:1993;228.
50. Iida H., Yuasa Y., Kibayashi C. J. Org. Chem. 45:1980;2938-2942.
51. Masaguer C.F., Raviña E. Tetrahedron Lett. 37:1996;5171-5174.
52. Sakamoto T., Nagano T., Kondo Y., Yamanaka H. Synthesis. 1990;215-218.
53. 2Areceptor interactions. A key structural feature that may play a prominent role in these interactions would be the benzylic carbonyl group. Eur. J. Med. Chem. 34:1999;441-447.
54. Loza I., Verde I., Orallo F., Fontenla J.A., Calleja J.M., Raviña E., Cortizo L., de Ceballos M. Bioorg. Med. Chem. Lett. 1:1991;717-720.
55. Cheng Y.C., Prusoff W. Biochem. Pharmacol. 22:1973;3099-3108.
56. Bradley P.B., Engel G., Feniuk W., Fozard J.R., Humphrey P.P.A., Middlemiss D.N., et al. Neuropharmacology. 25:1986;563-576.
57. Pazos A., Cortes R., Palacios J.M. Brain Res. 346:1985;231-245.
58. Wong D.T., Threlkeld P.G., Robertson D.W. Neuropsychopharmacol. 5:1991;43-47.
59. Loza I., Ferreiro T.G., Sanz F., Lozoya E., Rodriguez J., Manaut F., et al. J. Pharm. Sci. 82:1993;513-517.
60. Fukuda S., Su C., Lee T.J.F. J. Pharmacol. Exp. Ther. 239:1986;264-269.
61. Gruetter C.A., Lemke S.M., Anestis D.K., Szarek J.L., Valentovic M.A. Eur. J. Pharmacol. 217:1992;109-118.
62. Cohen M.L., Fuller R.W., Wiley K.S. J. Pharmacol. Exp. Ther. 218:1981;421-425.
63. Arunlaksana O., Schild H.O. Br. J. Pharmacol. 14:1959;48-58.
64. Vane J.R. Br. J. Pharmacol. 12:1957;344-349.
65. Van Rossum J.M. Arch. Int. Pharmacol. 143:1963;299.
66. Mackay D. J. Phar. Pharmacol. 30:1978;312-313.